AMH Test and Menopause Timing: Can It Predict When You'll Reach Menopause?

AMH is the most accurate single biomarker for predicting the timing of menopause, but its predictive power comes with important caveats. Longitudinal studies following women over decades have shown that AMH becomes undetectable approximately 2-5 years before the final menstrual period. When measured during the late reproductive years (age 40-50), AMH can estimate time to menopause within a range of roughly 2-4 years. When measured earlier (age 25-35), AMH provides a broader estimate of menopause timing but with less precision. This guide presents the data on how AMH declines across the reproductive lifespan, explains the accuracy and limitations of menopause prediction, and provides actionable guidance for women considering AMH testing for reproductive life planning.

This guide was prepared by the WellAlly Fertility Team, comprising board-certified reproductive endocrinologists with expertise in reproductive aging and menopause. The data presented is drawn from landmark longitudinal studies published in the Journal of Clinical Endocrinology and Metabolism, including the Tehrani et al. Tehran Lipid and Glucose Study and the Freeman et al. Penn Ovarian Aging Study. These studies followed thousands of women over 10-15 years to establish the relationship between AMH and menopause timing. Recommendations align with ACOG practice guidelines on the menopause transition.

AMH follows a highly predictable decline from birth through menopause. Understanding this trajectory is the foundation for menopause timing prediction.

AMH Trajectory by Age

The average age of natural menopause in the United States is 51 years, with a normal range of 45-55 years.

Graphical Representation of AMH Decline

While AMH declines smoothly on average, individual trajectories vary significantly. Some women maintain detectable AMH into their late 40s, while others reach undetectable levels by their early 40s. The rate of decline is not perfectly linear — it accelerates in the late 30s and early 40s as the remaining follicle pool shrinks below a critical threshold.

Key milestones in the AMH decline:

• AMH below 1.0 ng/mL: Typically occurs between ages 35-42; indicates diminished reserve
• AMH below 0.3 ng/mL: Typically occurs between ages 40-47; indicates approaching menopause
• AMH undetectable (＜ 0.05 ng/mL): Typically occurs 2-5 years before the final menstrual period

One of the most clinically useful findings from longitudinal research is the relationship between undetectable AMH and time to menopause. Multiple studies have established this correlation with high consistency.

The consensus from these studies: when AMH falls below the detection limit of standard assays, menopause occurs within approximately 2-5 years in the vast majority of women. This is the most reliable single-test prediction available for menopause timing.

The accuracy of AMH-based menopause prediction depends heavily on when the test is performed and what AMH level is found.

Prediction Accuracy by Age at Testing

Key insight: Prediction accuracy improves as women approach menopause. Testing at 25 provides only a rough estimate, while testing at 45 yields a much more precise prediction.

AMH testing for menopause prediction is most clinically useful in specific scenarios:

1. Women aged 35-40 planning future fertility: AMH helps estimate how many reproductive years remain and whether fertility preservation (egg freezing) should be considered urgently.

2. Women with family history of early menopause: If your mother or sisters experienced menopause before age 45, AMH testing can help assess whether you are on a similar trajectory.

3. Women with irregular cycles in their late 30s or 40s: AMH helps differentiate between perimenopause and other causes of cycle irregularity.

4. Women who have undergone ovarian surgery or chemotherapy: These treatments can accelerate ovarian aging. AMH monitoring helps assess the impact.

5. Women considering stopping contraception: If you are in your late 40s and wondering whether contraception is still necessary, AMH can help assess where you are in the menopause transition.

ASRM does not recommend routine AMH testing for menopause prediction in all women, but acknowledges its utility in these specific clinical situations.

Perimenopause — the transition period leading to menopause — is characterized by progressively declining AMH levels alongside increasing cycle irregularity.

AMH and follicle-stimulating hormone (FSH) are both used to assess menopause status, but they have different strengths.

Clinical consensus: AMH is superior for long-term menopause prediction because it changes earlier and more gradually. FSH is better for confirming that menopause is imminent or has occurred. Many clinicians use both tests together for the most complete picture.

Several important limitations should be understood:

1. Individual variation is substantial: Two women with the same AMH at age 35 may reach menopause 5-8 years apart. AMH provides statistical probability, not certainty.

2. Assay variability: Different laboratories use different AMH assays with varying detection limits. Results are not always directly comparable between labs.

3. External factors: Smoking, chemotherapy, ovarian surgery, and certain autoimmune conditions can accelerate the decline beyond what natural trajectory would predict.

4. Oral contraceptive effect: AMH may be suppressed 20-30% during combined oral contraceptive use, potentially leading to underestimation of reserve.

5. PCOS confounds prediction: Women with PCOS have elevated AMH that does not decline at the same rate as the general population, making menopause prediction less accurate.

6. Ethnic variation: Some studies suggest differences in AMH trajectories across ethnic groups, though data is still emerging.

Can AMH accurately predict the exact age I will reach menopause?

No. AMH can estimate menopause timing within a range of approximately 2-4 years when tested in your late 30s or 40s. It cannot pinpoint an exact age. Think of it as a weather forecast for the next week — directionally accurate but not precise to the day.

I am 30 with low AMH. Does this mean I will go through menopause early?

Low AMH at age 30 suggests an increased probability of earlier menopause compared to peers, but it is not definitive. Some women with low AMH at 30 maintain detectable levels into their late 40s. If early menopause is a concern, serial AMH testing every 1-2 years can track your individual trajectory.

Should I get tested for menopause prediction if I am not trying to conceive?

AMH testing for menopause prediction is reasonable if you have a family history of early menopause, are experiencing cycle changes, or want to plan for the menopause transition. However, routine testing in asymptomatic women under 40 is not currently recommended by major medical societies.

Is AMH better than FSH for predicting when menopause will happen?

Yes, for long-term prediction. AMH begins declining years before FSH rises, making it a better early warning system. FSH is more useful for confirming that menopause is near or has already occurred. The two tests together provide the most complete assessment.

If my AMH is undetectable, can I still get pregnant?

It is possible but unlikely. Undetectable AMH suggests very few remaining follicles, but sporadic ovulation can still occur during perimenopause. If pregnancy is desired, see a fertility specialist immediately. If pregnancy is not desired, continue contraception until 12 consecutive months without a period.

1. AMH is the best single biomarker for menopause timing prediction, but accuracy improves as you approach menopause and decreases with distance from it.
2. Undetectable AMH predicts menopause within 2-5 years with high reliability, based on multiple longitudinal studies with thousands of participants.
3. Prediction accuracy ranges from 2-4 years when tested in the late reproductive years, which is useful for planning but not a precise forecast.
4. AMH outperforms FSH for long-term prediction because it declines gradually over years, while FSH rises sharply only near menopause.
5. Individual variation limits precision — two women with identical AMH levels may still reach menopause years apart.
6. AMH testing is most useful for women aged 35-50 who have specific concerns about reproductive timeline, family history of early menopause, or cycle irregularity.